Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 9/20 | 0.37 |
| ▸ | KDR | P35968 | 9/20 | 0.37 |
| ▸ | MET | P08581 | 8/20 | 0.37 |
| ▸ | TEK | Q02763 | 6/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850647 | 0.92 | KDR (0.35) | SMN1; SMN2NPSR1LCKKDRMET | |
| SCHEMBL4237062 | 0.88 | SMN1; SMN2 (0.42) | SMN1; SMN2NPSR1MCHR1MEN1KMT2A | |
| SCHEMBL4233984 | 0.88 | KDR (0.38) | KDRMAPT | |
| SCHEMBL4233515 | 0.86 | HTR4 (0.43) | LCKKDRMETMEN1KMT2A | |
| SCHEMBL4229335 | 0.83 | KMT2A (0.37) | LCKKDRMETMEN1KMT2A | |
| SCHEMBL4233894 | 0.83 | MCHR1 (0.47) | SMN1; SMN2NPSR1KDRMCHR1MEN1 | |
| SCHEMBL4236062 | 0.83 | MCHR1 (0.47) | SMN1; SMN2NPSR1KDRMCHR1MEN1 | |
| SCHEMBL4233458 | 0.82 | ADRB2 (0.46) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4233951 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2NPSR1MCHR1MEN1KMT2A | |
| SCHEMBL4242226 | 0.81 | SMN1; SMN2 (0.43) | SMN1; SMN2NPSR1KDRMCHR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | claimed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | SMN1; SMN2 1538/4885NPSR1 12/4885LCK 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.